Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Short term Debt (2017 - 2025)

United Therapeutics' Short term Debt history spans 6 years, with the latest figure at $200.0 million for Q1 2025.

  • For Q1 2025, Short term Debt fell 50.0% year-over-year to $200.0 million; the TTM value through Mar 2025 reached $200.0 million, down 50.0%, while the annual FY2024 figure was $300.0 million, 25.0% down from the prior year.
  • Short term Debt for Q1 2025 was $200.0 million at United Therapeutics, down from $300.0 million in the prior quarter.
  • Across five years, Short term Debt topped out at $400.0 million in Q4 2023 and bottomed at $200.0 million in Q1 2025.
  • The 3-year median for Short term Debt is $400.0 million (2023), against an average of $342.9 million.
  • The largest annual shift saw Short term Debt surged 33.33% in 2024 before it tumbled 50.0% in 2025.
  • A 3-year view of Short term Debt shows it stood at $400.0 million in 2023, then fell by 25.0% to $300.0 million in 2024, then tumbled by 33.33% to $200.0 million in 2025.
  • Per Business Quant, the three most recent readings for UTHR's Short term Debt are $200.0 million (Q1 2025), $300.0 million (Q4 2024), and $400.0 million (Q3 2024).